Ensysce reports FY2022 net loss $24.2M, cash $3.1M; $3M equity raise; clinical milestones achieved

Ensysce Biosciences, Inc.

2024-Q1 EPS reported -$2.08 revenue$789,635

Q4 net loss $5.5M ($10.0M prior year); FY2022 net loss $24.2M ($29.1M prior year).
Cash at Dec 31, 2022 $3.1M, down from $12.3M year ago; raised $3M post-year-end at $0.84/share.
R&D expenses Q4 $6.4M (up from $2.2M prior year); FY $19.8M (up from $4.7M prior year) due to clinical trials.
Clinical progress: PF614 oral HAP study database locked Feb 2023; FDA guidance supports acute pain indication; PF614-MPAR Phase 1 fully enrolled.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Ensysce Biosciences, Inc. reported the fourth quarter of 2022 results: net income $5.5 million.

Period: the fourth quarter of 2022
Net income: $5.5 million
Result: reported results

Exact text from the filing

Net loss for the fourth quarter of 2022 was $5.5 million compared to $10.0 million for the fourth quarter of 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Ensysce Biosciences, Inc. reported the full year of 2022 results: net income $24.2 million.

Period: the full year of 2022
Net income: $24.2 million
Result: reported results

Exact text from the filing

For the full year of 2022, net loss was $24.2 million compared to $29.1 million for the full year of 2021.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Ensysce Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-009856

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.